by: Parent Project Muscular DystrophyFibroGen joined Parent Project Muscular Dystrophy for a webinar on February 2, 2022. During the webinar, FibroGen discussed the clinical rationale for the use of Pamrevlumab by highlighting its Phase 2 study in non-ambulatory participants with Duchenne and provided an update on its Phase 3 094 study in ambulatory participants with Duchenne.
